Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cost-effectiveness
100%
Clinical Trials
100%
Dutasteride
100%
Prostate Cancer
100%
Population-based
100%
High-risk Population
100%
Chemoprevention
100%
Placebo
50%
Incremental Cost
25%
Cost per QALY
25%
Usual Care
12%
Risk Reduction
12%
Prostate Cancer Screening
12%
Total Prostate-specific Antigen
12%
Benign Prostatic Hyperplasia
12%
Markov Model
12%
Acute Urinary Retention
12%
5α-reductase Inhibitors
12%
Single-negative
12%
Payer Perspective
12%
State of Health
12%
Negative Prostate Biopsy
12%
Medicine and Dentistry
Health Care Cost
100%
Clinical Trial
100%
Chemoprophylaxis
100%
Dutasteride
100%
Prostate Cancer
100%
High Risk Population
100%
Placebo
40%
Quality Adjusted Life Year
30%
Lifespan
20%
Prostate Specific Antigen
10%
Cancer Diagnosis
10%
Prostate Biopsy
10%
Health Status
10%
Prostate Hypertrophy
10%
Biopsy Technique
10%
Urinary Retention
10%
Steroid 5alpha Reductase Inhibitor
10%
Nursing and Health Professions
Chemoprophylaxis
100%
High Risk Population
100%
Prostate Cancer
100%
Dutasteride
100%
Clinical Trial
100%
Placebo
50%
Quality Adjusted Life Year
37%
Cancer Diagnosis
12%
Health Status
12%
Prostate Specific Antigen
12%
Prostate Hypertrophy
12%
Biopsy Technique
12%
Prostate Biopsy
12%
Urine Retention
12%
Steroid 5alpha Reductase Inhibitor
12%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Prostate Cancer
100%
Dutasteride
100%
Placebo
50%
Prostate Specific Antigen
12%
Prostate Hypertrophy
12%
Health Status
12%
Urine Retention
12%
Steroid 5alpha Reductase Inhibitor
12%